Electronic Supplementary Information

Synthetic preparation and immunological evaluation of β-

mannosylceramide and related N-acyl analogues

Sage A. Robinson,^a Jessica Yau,^b Masaki Terabe,^b Jay A. Berzofsky,^b Gavin F. Painter,^c Benjamin J. Compton,^{c*} and David S. Larsen^{*a}

^a Department of Chemistry, University of Otago, Dunedin, New Zealand; ^b Vaccine Branch, Centre for Cancer Research, National Cancer Institute, Bethesda, Maryland USA; ^c Ferrier Research Institute, Victoria University of Wellington, Wellington, New Zealand

Table of Contents

Gener	al Experimental5
HPLC a	analysis
Metho	ods and Materials for Assays
iNKT	Cell Hybridoma Stimulation Assay6
In viv	o lung metastasis assay
Experi	mental
1-((2'	S,3'S,4'R)-2'-Azido-3',4'-di- <i>O</i> -benzyl-1'-octadecanyl)-3,4,6-tri- <i>O</i> -benzyl-β-D-
gluco	pyranoside (16)
1-((2'	S,3'S,4' <i>R</i>)-2'-azido-3',4'-di- <i>O</i> -benzyl-1'-octadecanyl)-3,4,6-tri- <i>O</i> -benzyl-β-D-
mann	opyranoside (17)
1-[(2'	S,3'S,4'R)-2'- <i>N</i> -hexacosanamide-3',4'-di- <i>O</i> -benzyl-1'-octadecanyl]-2,3-di- <i>O</i> -benzyl-4,6- <i>O</i> -
benzy	vlidene-β-D-mannopyranoside (19)
<i>N</i> -[(1 (β-Μa	$S,2S,3R$)-2,3-dihydroxy-1-[(β -D-mannopyranosyloxy)methyl]heptadecyl] hexacosanamide anCer, 2)
1-((2' mann	$S,3'S,4'R$)-2'-azido-3',4'-di- <i>O</i> -benzyl-1'-octadecanyl)-2- <i>O</i> -benzoyl-3,4,6-tri- <i>O</i> -benzyl- α -D-opyranoside (22)
1-((2' ManF	$S,3'S,4'R$)-2'-Amino-1',3',4'-octadecanyl)- α -D-mannopyranoside-2,2,2-trifluoroacetate (α -Phs, 23)
N-[(1	S,2S,3R)-2,3-dihydroxy-1-[(α-D-mannopyranosyloxy)methyl]heptadecyl] hexacosanamide
(α-Μ	anCer, 20)
1-[(2'	S,3'S,4'R)-2'-[11''-(4-Fluorophenyl)-undecamidyl]-3',4'-di- <i>O</i> -benzyl-1'-octadecanyl-2,3-di-
<i>O</i> -bei	nzyl-4,6- <i>O</i> -benzylidene-β-D-mannopyranoside (26)12
11-(4	-Fluorophenyl)- <i>N</i> -[(1 <i>S</i> ,2 <i>S</i> ,3 <i>R</i>)-2,3-dihydroxy-1-[(β-D-
mann	opyranosyloxy)methyl]heptadecyl]undecanamide (28)
1-[(2'	S,3'S,4'R)-2'-[11''-(4-(4-Fluorophenoxy)phenyl)-undecamidyl]-3',4'-di- <i>O</i> -benzyl-1'-
octad	ecanyl]-2,3-di- <i>O</i> -benzyl-4,6- <i>O</i> -benzylidene-β-D-mannopyranoside (27)
1-[(2'	S,3'S,4'R)-2'-[11"-(<i>p</i> -(4-Fluorophenoxy)phenyl)-undecamidyl]-3',4'-di- <i>O</i> -acetyl-1'-
octad	ecanol]-2,3,4,6-tetra- <i>O</i> -acetyl-β-D-mannopyranoside (30)
11-(4	-(4-Fluorophenoxy)phenyl)- <i>N</i> -[(1 <i>S</i> ,2 <i>S</i> ,3 <i>R</i>)-2,3-dihydroxy-1-[(β-D-
mann	opyranosyloxy)methyl]heptadecyl] undecanamide (29)16
1-((2'	S,3'S,4'R)-2'-[<i>N-tert</i> -butoxycarbonylamino]-3',4'-di- <i>O</i> -benzyl-1'-octadecanol)-2,3-di- <i>O</i> -
benzy	/l-4,6- <i>O</i> -benzylidene-β-D-mannopyranoside (31)16
1-((2'	S,3'S,4'R)-2'-Amino-1',3',4'-octadecanyl)-β-D-mannopyranoside.TFA salt (32)
1-[(2'	S,3'S,4'R)-2'- <i>N</i> -[(11Z,14Z)-1''-oxo-11",14''-eicosadien-1"-yl]-3',4'-di- <i>O</i> -acetyl-1'-
octad	ecanyl]-2,3,4,6-tetra- <i>O</i> -acetyl-β-D-mannopyranoside (34)18

<i>N</i> -[(1 <i>S</i> ,2 <i>S</i> ,3 <i>R</i>)-2,3-Dihydroxy-1-[(β-D-mannopyranosyloxy)methyl]heptadecy eicosadienamide (33)	yl]-11 <i>Z</i> , 14 <i>Z</i> - 18
Figures for Supporting Information	20
_Figure SI-1 Stacked ¹ H NMR partial spectra of α -ManCer (20)(top) and β -M	anCer (2) (bottom)
Figure SI-2	21
NMR Spectra and HPLC Chromatograms	
Compound 8 (method 2). ¹ H NMR spectrum (500 MHz, CDCl ₃)	24
Compound 8 (method 2) ¹³ C NMR spectrum (125 MHz, CDCl ₃)	25
Compound 8 (method 2). HSQC spectrum.	26
Compound 11 . ¹ H NMR spectrum (500 MHz, CDCl ₃)	27
Compound 11 ¹³ C NMR spectrum (125 MHz, CDCl ₃)	28
Compound 13 . ¹ H NMR spectrum (500 MHz, CDCl ₃)	29
Compound 13 ¹³ C NMR spectrum (125 MHz, CDCl ₃). δ (ppm)	
Compound 13. HSQC spectrum	31
Compound 15 ¹ H NMR spectrum (500 MHz, CDCl ₃)	32
Compound 15 . ¹³ C NMR spectrum (125 MHz, CDCl ₃)	
Compound 16. ¹ H NMR spectrum (500 MHz, CDCl ₃)	35
Compound 16. ¹³ C NMR spectrum (500 MHz, CDCl ₃)	
Compound 17. ¹ H NMR spectrum (500 MHz, CDCl ₃)	37
Compound 17. ¹³ C NMR spectrum (125 MHz, CDCl ₃)	
Compound 19 . ¹ H NMR spectrum (500 MHz, CDCl ₃)	
Compound 19 . ¹³ C NMR spectrum (125 MHz, CDCl ₃)	40
Compound 2. ¹ H NMR spectrum (500 MHz, 2:1 CDCl ₃ :CD ₃ OD)	41
Compound 2 . ¹³ C NMR spectrum (125 MHz, 2:1 CDCl ₃ :CD ₃ OD)	42
Compound 2. HSQC spectrum	43
Figure SI-### Stacked ¹ H NMR partial spectra of α -ManCer 20 (top) and β -M	/anCer 2 (bottom)
HPLC chromatogram of 2	45
Compound 22. ¹ H NMR spectrum (500 MHz, CDCl ₃)	46
Compound 22. ¹³ C NMR spectrum (125 MHz, CDCl ₃)	47
Compound 23. ¹ H NMR spectrum (500 MHz, 2:1 CDCl ₃ :CD ₃ OD)	48
Compound 23. ¹³ C NMR spectrum (125 MHz, 2:1 CDCl ₃ :CD ₃ OD)	49
HPLC chromatogram of 23	50

Compound 20. ¹ H NMR spectrum (500 MHz, 2:1 CDCl ₃ :CD ₃ OD)	51
Compound 20. ¹³ C NMR spectrum (125 MHz, 2:1 CDCl ₃ :CD ₃ OD)	52
Compound 20. HSQC spectrum	53
HPLC chromatogram of 20	54
Compound 26. ¹ H NMR spectrum (500 MHz, CDCl ₃)	55
Compound 26 . ¹³ C NMR spectrum (125 MHz, CDCl ₃)	56
Compound 27. ¹ H NMR spectrum (500 MHz, CDCl ₃). β : α = 95:5	57
Compound 27. ¹³ C NMR spectrum (125 MHz, CDCl ₃)	58
Compound 28. ¹ H NMR spectrum (500 MHz, 2:1 CDCl ₃ :CD ₃ OD)	59
Compound 28. ¹³ C NMR spectrum (125 MHz, 2:1 CDCl ₃ :CD ₃ OD)	60
Compound 28. ¹⁹ F NMR spectrum (376 MHz, 2:1 CDCl ₃ :CD ₃ OD)	61
Compound 28. HSQC spectrum	62
HPLC chromatogram of 28	63
Compound 30 . ¹ H NMR spectrum (500 MHz, CDCl ₃)	64
Compound 30 . ¹³ C NMR spectrum (125 MHz, CDCl ₃)	65
Compound 30 . ¹⁹ F NMR spectrum (376 MHz, CDCl ₃)	66
Compound 29 . ¹ H NMR spectrum (500 MHz, 2:1 CDCl ₃ :CD ₃ OD)	67
Compound 29 . ¹³ C NMR spectrum (125 MHz, 2:1 CDCl ₃ :CD ₃ OD)	68
Compound 29 . ¹⁹ F NMR spectrum (376 MHz, 2:1 CDCl ₃ :CD ₃ OD)	69
Compound 29 . HSQC spectrum	70
HPLC chromatogram of 29	71
Compound 31 . ¹ H NMR spectrum (500 MHz, CDCl ₃)	72
Compound 32 . ¹ H NMR spectrum (500 MHz, 2:1 CDCl ₃ :CD ₃ OD)	74
Compound 32 . ¹³ C NMR spectrum (125 MHz, 2:1 CDCl ₃ :CD ₃ OD)	75
Compound 32 . ¹⁹ F NMR spectrum (376 MHz, 2:1 CDCl ₃ :CD ₃ OD)	76
Compound 32 . HSQC spectrum	77
HPLC chromatogram of 32	78
Compound 33 . ¹³ C NMR spectrum (125 MHz, 2:1 CDCl ₃ :CD ₃ OD)	79
HPLC chromatogram of 33	82
Compound 34 . ¹ H NMR spectrum (500 MHz, (CD ₃) ₂ CO)	83
Compound 34 . ¹³ C NMR spectrum (125 MHz, (CD ₃) ₂ CO)	84

General Experimental

Experiments requiring anhydrous conditions were performed under a dry nitrogen or argon atmosphere using apparatus heated and dried under vacuum, unless stated otherwise. Anhydrous dichloromethane (CH₂Cl₂), tetrahydrofuran (THF), toluene, acetonitrile (CH₃CN) and methanol (CH₃OH) were dried using the PURE SOLV MD-6 solvent purification system. 6 M HCl in 1,4-dioxane was prepared from 36% aqueous HCl and 1,4-dioxane. All other reagents were purchased as analytical or reagent grade and used without further purification. Aqueous solutions of sodium chloride (NaCl), sodium bicarbonate (NaHCO₃) and ammonium chloride (NH₄Cl) were saturated. Reactions performed at room temperature (rt) were carried out at approximately 20 °C and reaction temperatures from -78 °C to 0 °C were obtained using the following cooling bath mixtures: acetone/dry ice, -78 °C; acetonitrile/dry ice, -40 °C; NaCl/ice, -15 °C; water/ice, 0 °C. Reactions were monitored by thin layer chromatography (TLC) carried out on 0.2 mm Kieselgel F254 (Merck) silica gel plates using UV light as a visualising agent and then stained and developed with heat using either vanillin in ethanolic sulfuric acid, ammonium heptamolybdate and cerium sulfate in aqueous sulfuric acid, or potassium permanganate and potassium carbonate in aqueous sodium hydroxide. Separation of mixtures was performed by flash chromatography using 0.063-0.1 mm silica gel with the indicated eluent. Infrared (IR) spectra were recorded on a Bruker Optics Alpha FT-IR spectrometer with a diamond Attenuated Total Reflectance (ATR) top plate. No sample preparation was required. Absorption peaks are reported as wavenumbers (v, cm⁻¹). NMR spectra were recorded on a Varian 400-MR spectrometer operating at 400 MHz for ¹H nuclei and 100 MHz for ¹³C nuclei at 25 °C, or a Varian 500 MHz AR Premium Shielded Spectrometer at operating at 500 MHz for ¹H nuclei and 125 MHz for ¹³C nuclei at 25 °C. ¹H NMR chemical shifts are reported in parts per million (ppm) relative to the chloroform (CDCl₃, δ 7.26), or dimethyl sulfoxide (DMSO-d6, δ 2.50) peak. ¹H NMR values are reported as chemical shifts δ multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; m, multiplet), coupling constant (J, Hz) and relative integral. Coupling constants were taken directly from the spectra. ¹³C NMR chemical shifts are reported in ppm relative to the chloroform (CDCl₃, δ 77.0), or dimethyl sulfoxide (DMSO-d6, δ 39.5) peak. ¹³C NMR values are reported as chemical shifts δ and assignment. Decoupled ¹⁹F NMR spectra were recorded on a Varian 400-MR spectrometer operating at 376 MHz at 25 °C and data are expressed in ppm. Assignments were made with the aid of DEPT, gCOSY, gHSQC, and gHMBC experiments. Mass spectra were recorded on a Bruker micrOTOF-Q II mass spectrometer by electrospray ionisation in

positive and negative mode. High-resolution mass spectra (HRMS) were obtained with a nominal resolution of 5,000 to 10,000.

HPLC analysis

Synthetic purity of compounds for biological testing was assessed by analytical RP-HPLC on an Agilent 1260 Infinity Quaternary HPLC equipped with both an Agilent 1260 Multiple Wavelength Detector and either an Agilent 6130 single quadrupole mass spectroscopic detector using ESI (peak identification) or a Dionex Corona Ultra RS charged aerosol detector (CAD) (synthetic purity). Using a Phenomenex Kinetex 100Å C18 (2.6 μ m, 3.0 x 50 mm) functionalized silica column. The standard method for purity assessment: line A = H₂O, line B = CH₃OH, both modified with 0.5% TFA, flow rate = 0.50 mL min⁻¹, gradient = 60% -100% line B (4 mins), 100% line B(8 mins), 100% - 60% line B (1 min), 60% line B (2 mins).

Methods and Materials for Assays

Cell lines. The iNKT hybridoma cell line, DN32.D3, was obtained from Albert Bendelac (University of Chicago, Chicago, Illinois, USA) and cultured in RPMI 1640 medium (Gibco) supplemented with 10% FCS (Corning), L-glutamine (Gibco), sodium pyruvate (Gibco), nonessential amino acids (Gibco), and 2-mercaptoethanol (5×10^{-5} M) (Gibco). The CT26 colon carcinoma was maintained in RPMI 1640, containing the supplements above except for the 2-mercaptoethanol. Cells were cultured in an atmosphere of 37°C and 5% CO₂.

<u>Mice.</u> Female BALB/c mice were purchased from Animal Production Colonies, Frederick Cancer Research Facility, National Cancer Institute, or The Jackson Laboratory. Female C57BL/6 mice were purchased from Animal Production Colonies, Frederick Cancer Research Facility, National Cancer Institute.

iNKT Cell Hybridoma Stimulation Assay

Splenocytes were harvested from mice, and the single cell suspension was depleted of erythrocytes with ACK Lysis Buffer (Lonza, Basel, Switzerland). T-cells were depleted from splenocytes using CD90.2 magnetic beads (Miltenyi Biotec, San Diego, CA) and autoMACS (Miltenyi Biotec, San Diego, CA). The negative fraction was collected and used as a source of antigen presenting cells (APCs). APCs (1×10^6 cells/well) were co-cultured with the hybridoma clone (5×10^4 cells/well) in 96- well flat-bottom plate in the presence of an analogue of β -ManCer, β -ManCer, α -GalCer, or vehicle. After an 18h incubation at 37 °C 5% CO₂, supernatants were collected and IL-2 concentrations were determined by ELISA (eBioScience, San Diego, CA) according to the manufacturer's instructions.

In vivo lung metastasis assay

CT26 cells (5×10^5 cells) in 0.2 ml PBS were injected i.v. into the tail vein of BALB/c mice. The analogues of β -ManCer, β -ManCer, or vehicle (0.00025% Tween 20 in PBS) were injected i.p. (in 0.2 ml PBS) within 1 hour after tumour challenge. Mice were sacrificed 14– 16 days after the tumour challenge. The lungs were stained with 10% India Ink and fixed with Fekete's solution. The number of lung nodules were macroscopically enumerated. All animal experiments were performed in accordance with NIH policies and approved by the NCI Animal Care and Use Committee.

Experimental

1-((2'S,3'S,4'R)-2'-Azido-3',4'-di-O-benzyl-1'-octadecanyl)-3,4,6-tri-O-benzyl-β-Dglucopyranoside (16)

Sodium methoxide solution (2.5M, 5 mL, 12.5 mmol) was added dropwise to a solution of glycoside **15** (346 mg, 0.347 mmol) in methanol (10 mL). The reaction was stirred overnight at rt then neutralised with amberlite IR-120 (H⁺ form). The solution was filtered through Celite washed with methanol and the solvent removed *in vacuo* to give the residue. The residue was diluted with EtOAc and washed with 50% aqueous NaHCO₃ and the organic concentrated *in vacuo* to afford an analytically pure sample of the *title compound* **16** (318 mg, 0.333 mmol, 96%) as a white solid that was used without further purification. $\delta_{\rm H}(400 \text{ MHz}, \text{CDCl}_3)$: 7.44 – 7.27 (25H, m), 7.18 (2H, dd, *J* = 7.2, 2.3 Hz), 4.95 (1H, d, *J* = 11.3 Hz), 4.84 (2H, d, *J* = 11.2 Hz), 4.72 – 4.65 (2H, m), 4.61 – 4.52 (4H, m), 4.49 (1H, d, *J* = 12.2 Hz), 4.26 – 4.22 (1H, m, H-1), 4.19 (1H, dd, *J* = 10.5, 6.6 Hz), 3.88 (1H, dd, *J* = 10.6, 3.2 Hz), 3.79 – 3.69 (4H, m), 3.64 (2H, td, *J* = 6.8, 5.5, 3.0 Hz), 3.60 – 3.56 (2H, m), 3.42 (1H, dt, *J* = 9.6, 3.2 Hz), 2.41 (1H, br s), 1.75 – 1.20 (26H, m), 0.89 (3H, t, *J* = 6.6 Hz); $\delta_{\rm C}(101 \text{ MHz}, \text{CDCl}_3)$: 138.80, 138.42, 138.26, 138.25, 138.09, 128.59, 128.57, 128.53, 128.51, 128.48, 128.26, 128.25, 128.13,

128.10, 128.06, 127.93, 127.89, 127.88, 127.82, 127.72, 102.80 (d, ${}^{1}J_{CH} = 162.54$ Hz, C-1), 84.53, 79.37, 78.96, 77.56, 75.42, 75.26, 75.15, 74.89, 73.93, 73.61, 72.20, 69.54, 68.90, 61.82, 32.08, 30.02, 29.92, 29.86, 29.85, 29.83, 29.82, 29.78, 29.76, 29.52, 25.49, 22.85, 14.28; HRMS (ESI-pos): calcd for C₅₉H₇₇O₈N₃Na [M + Na]⁺ m/z 978.5603, found m/z 978.5626.

$1-((2'S,3'S,4'R)-2'-azido-3',4'-di-O-benzyl-1'-octadecanyl)-3,4,6-tri-O-benzyl-\beta-D-mannopyranoside (17)$

A solution of glucoside 16 (318 mg, 0.333 mmol) in anhydrous CH₂Cl₂ (5 mL) at rt under Ar was treated with Dess-Martin periodinane (460 mg, 1.030 mmol) in one portion. The resulting suspension was stirred for 16 hrs then diluted with CH₂Cl₂ and filtered through Celite. The filtrate was washed with 50% sat. aqueous NaHCO₃. The combined organic layers were dried and concentrated in vacuo to give the residue which was triturated with di-isopropyl ether to remove excess Dess-Martin related materials and filtered. The filtrate was concentrated in *vacuo* to afford the intermediate ulose that was used directly in the next step. L-Selectride (1M in THF, 700 µL, 0.700 mmol) was added to a solution of the crude ulose (318 mg, 0.333 mmol) in anhydrous THF (1 mL, 3 mL per mmol) at -78 °C under Ar. After 10 min the reaction was stopped by the addition of acetic acid. The reaction was warmed to rt, diluted with CH₂Cl₂and washed with 2M HCl, followed by sat. aq. NaHCO₃. The combined organic extracts were concentrated in vacuo to afford the crude residue which was purified by column chromatography (PE to 7:1 PE/EtOAc) to afford a single diastereomer of the title compound 17 (140 mg, 0.146 mmol, 44% over two steps) as a colourless oil. $\delta_{\rm H}(500 \text{ MHz}, \text{CDCl}_3)$: 7.42 -7.25 (22H, m), 7.23 (3H, ddd, J = 9.5, 7.0, 3.1 Hz), 4.90 (1H, d, J = 10.8 Hz), 4.78 (1H, d, J= 11.9 Hz), 4.70 - 4.65 (3H, m), 4.60 (1H, d, J = 12.2 Hz), 4.57 - 4.50 (4H, m), 4.33 (1H, s, H-1), 4.16 (1H, dd, J = 10.5, 7.4 Hz), 4.08 (1H, d, J = 3.1 Hz), 3.91 (1H, t, J = 9.4 Hz), 3.85 (1H, dd, J = 10.5, 3.4 Hz), 3.81 (1H, ddd, J = 7.5, 5.4, 3.4 Hz), 3.74 - 3.71 (2H, m), 3.65 (1H, m), 3.65 (1H, m))t, J = 5.0 Hz), 3.61 (1H, dt, J = 7.0, 4.1 Hz), 3.52 (1H, dd, J = 9.0, 3.1 Hz), 3.36 (1H, ddd, J = 9.7, 4.3, 2.8 Hz), 2.34 (1H, b, OH), 1.74 - 1.52 (2H, m), 1.45 - 1.10 (23H, m), 0.89 (3H, t, J = 6.9 Hz); $\delta_{C}(126 \text{ MHz}, \text{CDCl}_{3})$: 138.46, 138.41, 138.05, 138.01, 128.68, 128.62, 128.56, 128.52, 128.51, 128.47, 128.42, 128.36, 128.25, 128.21, 128.08, 128.05, 128.00, 127.98, 127.95, 127.90, 127.86, 127.80, 127.67, 99.73 (d, ${}^{1}J_{CH}$ = 157.18 Hz, C-1), 81.44, 79.25, 79.21, 75.62, 75.31, 74.27, 73.89, 73.60, 72.15, 71.47, 69.45, 69.21, 68.26, 61.93, 32.08, 30.09,

29.95, 29.86, 29.83, 29.82, 29.79, 29.76, 29.52, 25.39, 22.85, 14.28; HRMS (ESI-pos): calcd for C₅₉H₇₇O₈N₃Na [M + Na]⁺ *m/z* 978.5603, found *m/z* 978.5619.

1-[(2'*S*,3'*S*,4'*R*)-2'-*N*-hexacosanamide-3',4'-di-*O*-benzyl-1'-octadecanyl]-2,3-di-*O*-benzyl-4,6-*O*-benzylidene-β-D-mannopyranoside (19)

To a solution of azide 8 ($\alpha/\beta = 5.95$) (160 mg, 0.168 mmol) in anhydrous THF (5 mL) at 0 °C under argon was added trimethylphosphine (1M in THF, 1100 µL, 1.100 mmol). After warming to rt over 1 hr. the solution was then stirred at rt for 4 hrs before the addition of NaOH (2M, 4 mL). The mixture was stirred at rt overnight to hydrolyse the imino-phosphorane, then the reaction was diluted with CH₂Cl₂, washed with water and the volatiles were removed in *vacuo* to give the crude amine intermediate **18** as a colourless oil. HRMS (ESI-pos): calcd for $C_{59}H_{78}O_8N [M + H]^+ m/z$ 928.5722, found m/z 928.5728. EDCI-HCl (100 mg, 0.518 mmol) and HOBt (80 mg, 0.579 mmol) were added to a stirred suspension of hexacosanoic acid (99 mg, 0.236 mmol) in CH₂Cl₂/DMF (10:4, 14 mL) at rt. After 30 min a solution of crude amine 18 (0.168 mmol) in anhydrous CH_2Cl_2 (5 mL) was added followed by DIPEA (200 μ L, 1.142 mmol) and the reaction stirred at rt overnight. The reaction was diluted with CH₂Cl₂, washed with water and the aqueous layer re-extracted with EtOAc. The combined organic extracts were concentrated in vacuo to give the crude material which was purified by column chromatography (PE, to 5:1 PE:EtOAc) to give the *title compound* **19** (178 mg, 0.136 mmol, 81% over two steps) both as white solids. $R_f = 0.36$ (5:1 PE/EtOAc); $\delta_H(500 \text{ MHz}, \text{CDCl}_3)$: 7.55 – 7.27 (25H, m), 5.67 (1H, d, J = 8.3 Hz), 5.62 (1H, s), 4.91 (1H, d, J = 12.2 Hz), 4.82 (1H, d, J = 12.3 Hz), 4.77 (1H, d, J = 11.5 Hz), 4.71 (1H, d, J = 12.4 Hz), 4.65 - 4.52 (4H, J = 12.4 Hz), 4.55 - 4.52 (4Hm), 4.45 - 4.35 (2H, m), 4.26 (1H, dd, J = 10.4, 4.8 Hz), 4.19 (1H, t, J = 9.6 Hz), 4.08 (1H, dd, J = 10.3, 7.8 Hz), 3.96 - 3.84 (2H, m), 3.83 - 3.74 (2H, m, H-1), 3.57 (2H, m), 3.26 (1H, td, *J* = 9.7, 4.8 Hz), 2.22 – 1.88 (2H, m), 1.76 – 1.60 (2H, m), 1.35 – 1.20 (70H, m), 0.90 (6H, t, J = 6.8 Hz,); $\delta_{\rm C}(126$ MHz, CDCl₃): 172.91, 138.63, 138.61, 138.57, 138.42, 137.66, 128.98, 128.55, 128.50, 128.43, 128.41, 128.29, 128.03, 127.96, 127.90, 127.79, 127.69, 127.67, 126.18, 102.17 (d, ${}^{1}J_{CH} = 155.29$ Hz C-1), 101.56, 80.57, 79.72, 78.76, 77.95, 76.06, 74.81, 73.69, 72.55, 72.17, 68.71, 68.67, 67.66, 49.88, 36.89, 32.06, 30.52, 29.94, 29.86, 29.83, 29.79, 29.69, 29.54, 29.52, 29.51, 29.49, 26.04, 25.76, 22.83, 14.26; HRMS (ESI-pos): calcd for $C_{85}H_{127}O_9NNa [M + Na]^+ m/z$ 1328.9403 found m/z 1328.9420; Anal. Calcd for $C_{85}H_{127}NO_9$: C, 78.12; H, 9.80; N, 1.07. Found C, 78.06; H, 9.99; N, 1.15.

N-[(1*S*,2*S*,3*R*)-2,3-dihydroxy-1-[(β-D-mannopyranosyloxy)methyl]heptadecyl] hexacosanamide (β-ManCer, 2)

To a solution of glycolipid 19 (251 mg, 0.192 mmol) in CH₂Cl₂/MeOH (1:1, 20 mL) was added 10% palladium on carbon (52 mg, 0.049 mmol). The stirred reaction mixture was degassed under vacuum and backfilled with hydrogen three times then left to stir overnight under a balloon of hydrogen. The hydrogen atmosphere was removed and the grey precipitate that formed during the reaction was dissolves on dilution with hot EtOH. The solution was then filtered through Celite and washed with excess hot EtOH. The solvents were removed in vacuo to give the crude material which was precipitated by dissolving in hot ethanol and triturating out of solution with dropwise addition of water, once the precipitate formed the mixture was heated to re-dissolve. The resulting solution was allowed to cool slowly to rt and then cooled in the freezer (-20°C), the resulting precipitate was filtered through a Hirsch funnel and dried to a constant weight affording the known^{1, 2} title compound **2** (151 mg, 0.176 mmol, 92%) as a white solid. $R_f = 0.41$ (15% MeOH:CHCl₃); $\delta_H(500 \text{ MHz}, 2:1 \text{ CDCl}_3:\text{CD}_3\text{OD}): 4.47$ (1H, s), 4.17 (1H, dt, J = 7.1, 4.1 Hz), 4.04 (1H, dd, 10.3, 3.9 Hz), 3.86 (2H, dd, J = 12.3, 2.7 Hz), 3.71 (2H, td, J = 11.9, 11.0, 5.0 Hz), 3.62 – 3.50 (3H, m), 3.43 (1H, dd, J = 9.4, 3.3 Hz), 3.20 (1H, ddd, J = 8.9, 5.9, 2.5 Hz), 2.16 (2H, t, J = 7.6 Hz), 1.65 - 1.46 (4H, m), 1.40 - 1.18 (75H, J = 7.6 Hz))s), 0.84 (6H, t, J = 6.8 Hz); $\delta_{C}(126$ MHz, 2:1 CDCl₃:CD₃OD): 174.82, 100.49 (d, ${}^{1}J_{CH} = 158.16$ Hz, C-1), 77.02, 74.47, 74.25, 72.40, 71.23, 68.53, 67.71, 62.04, 50.66, 36.88, 32.43, 32.32, 30.18, 30.16, 30.12, 30.10, 30.08, 30.06, 30.03, 29.96, 29.83, 29.77, 29.76, 29.74, 26.34, 26.31, 23.05, 14.26; HRMS (ESI-pos): calcd for C₅₀H₉₉O₉NNa $[M + Na]^+ m/z$ 880.7212 found m/z880.7227; Anal. Calcd for C₅₀H₉₉NO₉·H₂O: C, 68.53; H, 11.62; N, 1.60. Found C, 68.41; H, 11.75; N. 1.59.

1-((2'S,3'S,4'R)-2'-azido-3',4'-di-O-benzyl-1'-octade $canyl)-2-O-benzyl-3,4,6-tri-O-benzyl-\alpha-D-mannopyranoside (22)$

Triflic acid (5 µL, 0.057 mmol) was added to a mixture of **7** (80 mg, 0.153 mmol), thioglycoside **21** (121 mg, 0.186 mmol), and NIS (60 mg, 0.253 mmol) in anhydrous CH₂Cl₂ (5 mL) containing pre-activated 4Å MS at -10°C under argon. The reaction was warmed slowly to rt and after ca. 4 hours was diluted with CH₂Cl₂. The organic layer was washed with saturated aqueous NaHCO₃ and Na₂S₂O₃ solutions then concentrated *in vacuo* to give the crude material which was purified by column chromatography (PE to 6:1 PE/EtOAc) to afford the *title compound* **22** (120 mg, 0.113 mmol, 74%) as a colourless oil. $\delta_{\rm H}(500 \text{ MHz}, \text{CDCl}_3)$: 8.14 – 7.98 (2H, m), 7.56 (1H, td, 7.4, 1.3 Hz), 7.43 – 7.16 (27H, m), 5.65 (1H, d, 2.0 Hz, *H*-2), 4.96 (1H, d, 1.9 Hz, *H*-1), 4.88 (1H, d, *J* = 10.8 Hz), 4.78 (1H, d, *J* = 11.4 Hz), 4.69 (2H, dd, *J* =

11.6, 4.8 Hz), 4.64 – 4.45 (6H, m), 4.14 – 4.08 (3H, m), 3.86 – 3.80 (2H, m), 3.78 (1H, ddd, J = 8.3, 5.4, 2.8 Hz), 3.65 (2H, dd, J = 9.5, 2.1 Hz), 3.60 (2H, td, J = 10.3, 9.5, 6.0 Hz), 1.72 – 1.62 (1H, m), 1.50 – 1.60 (3H, m), 1.37 – 1.47 (1H, m), 1.21 – 1.35 (21H,m), 0.89 (3H, t, J = 6.6 Hz); $\delta_{\rm C}(126$ MHz, CDCl₃): 165.77, 138.55, 138.41, 138.11, 137.95, 133.27, 130.12, 130.01, 128.56, 128.55, 128.53, 128.47, 128.43, 128.25, 128.20, 128.11, 127.98, 127.82, 127.74, 127.66, 127.62, 98.54 (d, $^{1}J_{\rm CH} = 166.32$ Hz, *C*-1), 79.39, 79.27, 78.17, 75.40, 74.26, 73.87, 73.57, 72.29, 72.09, 71.71, 68.97, 68.90, 62.15, 32.08, 30.08, 29.93, 29.86, 29.83, 29.82, 29.80, 29.76, 29.52, 25.48, 22.85, 14.28; HRMS (ESI-pos): calcd for C₆₆H₈₁O₉N₃Na [M + Na]⁺ m/z 1082.5865, found m/z 1082.5837.

1-((2'S,3'S,4'R)-2'-Amino-1',3',4'-octadecanyl)-α-D-mannopyranoside-2,2,2trifluoroacetate (α-ManPhs, 23)

To a solution of glycoside 22 (120 mg, 0.113 mmol) in MeOH (10 mL) was added freshly prepared sodium methoxide solution (2.5M in MeOH, 80 μ L, 0.100 mmol) and the reaction mixture was stirred at rt for 3 hours. The reaction was diluted with CH₂Cl₂ and concentrated in vacuo. The resulting white solid was dissolved in CH₂Cl₂ and washed with brine. The solvent was removed *in vacuo* to give a white solid which was used directly in the next step. This was dissolved in CH₂Cl₂/MeOH (1:1, 6 mL) along with 1M hydrochloric acid (400 µL, 0.400 mmol). 10% palladium on carbon (11 mg) was added and the mixture was stirred hydrogen overnight. The hydrogen atmosphere was removed, the reaction diluted with hot EtOH, and filtered through Celite. The solvents were removed in vacuo to give the crude material as its hydrochloride salt. The residue was purified by C18 reverse phase chromatography (Isolute C-18(EC) with a gradient of H₂O (0.05% TFA) and MeCN 80:20 to 0:100 eluting around 60:40). The fractions containing the target molecule were combined and freeze-dried overnight to give the *title compound* **23** (33 mg, 0.055 mmol, 49%) as a lyophilized white solid. $\delta_{\rm H}$ (500 MHz, 2:1, CDCl₃:CD₃OD): 4.75 (1H, d, J = 1.7 Hz), 4.13 – 3.95 (1H, m), 3.88 – 3.79 (2H, m), 3.68 (2H, ddd, J = 11.4, 5.7, 2.4 Hz), 3.63 - 3.53 (3H, m), 3.53 - 3.45 (2H, m), 3.42 - 3.35 (1H, m))m), 1.75 (1H, br t, J = 10.0 Hz), 1.57 – 1.45 (1H, m), 1.35 – 1.15 (24H, s), 0.84 (3H, t, J = 6.8Hz); $\delta_{\rm C}(126 \text{ MHz}, 2:1, \text{CDCl}_3:\text{CD}_3\text{OD}): 101.00 \text{ (d, }^{1}J_{\rm CH} = 171.36 \text{ Hz } C-1), 73.67, 72.70, 71.99,$ 71.43, 70.41, 67.73, 64.00, 62.12, 54.04, 34.64, 32.22, 29.98, 29.94, 29.65, 25.54, 22.95, 14.20; δ_F(376 MHz, 2:1, CDCl₃:CD₃OD): -75.98; HRMS (ESI-pos): calcd for C₂₄H₅₀O₈N [M + H]⁺ m/z 480.3531 found m/z 480.3515.

N-[(1*S*,2*S*,3*R*)-2,3-dihydroxy-1-[(α-D-mannopyranosyloxy)methyl]heptadecyl] hexacosanamide (α-ManCer, 20)

TEA (200 µL, 1.424 mmol) then isopropyl chloroformate solution (70 µL, 0.070 mmol) was added to a mixture of cerotic acid (21 mg, 0.066 mmol) in anhydrous CH₂Cl₂ (5mL) under an argon atmosphere, and the resulting solution was stirred at rt for 50 min. This was added to a solution of 23 (31 mg, 0.052 mmol) in anhydrous DMF (5 mL) at 0 °C under argon and with the exclusion of light. After 5 min the ice bath was removed and the reaction was warmed to rt overnight. The reaction was diluted with MeOH and the solvents were removed in vacuo to give the residue which was absorbed onto silica gel from a mixture of warm MeOH:CHCl₃ and purified by column chromatography (CHCl₃ to 40% MeOH:CHCl₃) to give the known³ title compound **20** (42 mg, 0.049 mmol, 94%) as a white solid. $\delta_{H}(500 \text{ MHz}, 2:1 \text{ CDCl}_{3}:\text{CD}_{3}\text{OD})$: 7.29 (1H, d, J = 8.8 Hz), 4.73 (1H, d, J = 1.7 Hz), 4.18 – 4.11 (1H, m), 3.87 – 3.75 (3H, m), 3.70 (1H, dd, *J* = 11.9, 5.1 Hz), 3.66 (1H, dd, *J* = 9.3, 3.2 Hz), 3.64 – 3.56 (2H, m), 3.53 – 3.42 (3H, m), 2.16 (2H, t, J = 7.6 Hz), 1.73 – 1.42 (5H, m,), 1.30 – 1.18 (67H, m), 0.84 (6H, t, J = 6.8 Hz); $\delta_{C}(126 \text{ MHz}, 2:1 \text{ CDCl}_{3}:\text{CD}_{3}\text{OD}): 175.07, 100.90 \text{ (d, } {}^{1}J_{CH} = 158.16 \text{ Hz}, C-1), 74.93,$ 73.24, 72.49, 71.57, 70.85, 67.68, 67.06, 61.97, 51.37, 36.73, 32.70, 32.21, 30.04, 30.00, 29.96, 29.92, 29.85, 29.71, 29.64, 26.21, 26.14, 22.94, 14.21; HRMS (ESI-pos): calcd for $C_{50}H_{99}O_9NNa [M + Na]^+ m/z 880.7212$ found m/z 880.7194.

1-[(2'S,3'S,4'R)-2'-[11''-(4-Fluorophenyl)-undecamidyl]-3',4'-di-*O*-benzyl-1'octadecanyl-2,3-di-*O*-benzyl-4,6-*O*-benzylidene-β-D-mannopyranoside (26)

To a solution of azide **8** ($\alpha/\beta = 5:95$) (149 mg, 0.156 mmol) in anhydrous THF (10 mL) at 0 °C under argon was added trimethylphosphine (1M in THF, 1.100 mL, 1.100 mmol). The mixture was warmed to rt over 1 hr. and then stirred at rt for 4 hrs. NaOH (2M, 4 mL) was added to the reaction mixture and the resulting solution stirred at rt overnight. The reaction was diluted with CH₂Cl₂, washed with water and solvents were removed *in vacuo* to give amine intermediate **18** as a colourless oil. R_f = 0.55 (10% MeOH in CHCl₃); HRMS (ESI-pos): calcd for C₅₉H₇₈O₈N [M + H]⁺ m/z 928.5722, found m/z 928.5728. EDCI-HCl (95 mg, 0.498 mmol) and HOBt (78 mg, 0.568 mmol) were added to a stirred suspension of 11-(4-fluorophenyl)undecanoic acid **24**^{4, 5} (60 mg, 0.213 mmol) in anhydrous CH₂Cl₂/DMF (10:4, 7 mL) at rt under argon. After 30 min a solution of **18** (0.156 mmol) in CH₂Cl₂ (5 mL) was added followed by DIPEA (190 µL, 1.085 mmol) and the reaction stirred at rt overnight. The reaction was diluted with CH₂Cl₂, washed twice with 2M aqueous NaOH (to remove excess acid) and brine. The combined organic extracts were concentrated *in vacuo* to give the residue which was purified by column chromatography (PE, to 6:1 PE:EtOAc) the *title compound* **26** (129 mg, 0.108 mmol, 70%) as

a colourless oil. $\delta_{\rm H}(500 \text{ MHz}, \text{CDCl}_3)$: 7.53 – 7.21 (25H, m), 7.11 (2H, ddd, J= 8.7, 5.8, 3.2 Hz), 6.95 (2H, td, J= 8.7, 2.2 Hz), 5.65 (1H, d, J= 8.4 Hz), 5.60 (1H, s), 4.89 (1H, d, J= 12.3 Hz), 4.80 (1H, d, J= 12.2 Hz), 4.75 (1H, d, J= 11.5 Hz), 4.69 (1H, d, J= 12.5 Hz), 4.61 (1H, d, J= 9.4 Hz), 4.59 (1H, d, J= 10.5 Hz), 4.56 (1H, d, J= 6.9 Hz), 4.53 (1H, d, J= 6.9 Hz), 4.41 – 4.35 (2H, m), 4.25 (1H, dd, J= 10.4, 4.8 Hz), 4.17 (1H, t, J= 9.6 Hz), 4.06 (1H, dd, J= 10.3, 7.9 Hz), 3.90 – 3.83 (2H, m), 3.80 – 3.74 (2H, m), 3.59 – 3.52 (2H, m), 3.24 (1H, td, J= 9.7, 4.9 Hz), 2.55 (2H, t, J= 8.0 Hz), 1.93 (2H, dtd, J= 23.1, 14.7, 6.9 Hz), 1.70 – 1.45 (8H, m), 1.33 – 1.20 (2634H, m), 0.88 (3H, t, J= 6.9 Hz); $\delta_{\rm C}(126 \text{ MHz}, \text{CDCl}_3)$: 172.92, 161.25 ($^{1}J_{\rm CF}$ = 242.7 Hz), 138.65, 138.64 (d, $^{4}J_{\rm CF}$ = 3.1 Hz), 138.56, 138.44, 137.67, 129.76 (d, $^{3}J_{\rm CF}$ = 7.7 Hz), 129.02, 128.59, 128.57, 128.53, 128.52, 128.45, 128.34, 128.31, 128.05,127.98, 127.82, 127.69, 126.20, 115.03 (d, $^{2}J_{\rm CF}$ = 21.0 Hz), 102.21 (d, $^{1}J_{\rm CH}$ = 155.50 Hz, *C*-1), 101.59, 80.63, 79.72, 78.78, 77.95, 76.06, 74.82, 73.71, 72.57, 72.20, 68.70, 67.68, 49.93, 36.89, 35.27, 32.08, 31.76, 30.57, 29.96, 29.87, 29.85, 29.82, 29.72, 29.65, 29.62, 29.58, 29.52, 29.35, 26.06, 25.75, 22.84, 14.27; $\delta_{\rm F}(376 \text{ MHz}, \text{CDCl}_3)$: -118.66 (tt, J= 9.4, 5.6 Hz); HRMS (ESI-pos): calcd for C₇₆H₁₀₀O₉NFNa [M + Na]⁺ m/z 1212.7274 found m/z 1212.7249.

11-(4-Fluorophenyl)-N-[(1S,2S,3R)-2,3-dihydroxy-1-[(β -D-mannopyranosyloxy)methyl]heptadecyl]undecanamide (28)

To a solution of 26 (87 mg, 0.073 mmol) in CH₂Cl₂/MeOH (1:1, 20 mL) was added 10% palladium on carbon (18 mg, 0.017 mmol). The stirred reaction mixture was degassed under vacuum and backfilled with hydrogen three times then left to stir overnight under a balloon of hydrogen. The hydrogen atmosphere was removed and after dilution with MeOH the solution was filtered through Celite and washed with CH₂Cl₂/MeOH followed by approx. 50 mL of hot EtOH. The solvents were removed *in vacuo* to give the crude material which was precipitated by dissolving in hot ethanol and triturating out of solution by dropwise addition of water. Once a precipitate formed the mixture was heated to re-dissolve and the resulting solution was allowed to cool slowly to rt and then cooled in ice. The resulting precipitate was filtered through a Hirsch funnel and dried to a constant weight affording the *title compound* 28 (45 mg, 0.061 mmol, 83%) as a white solid. $\delta_{\rm H}(500 \text{ MHz}, 2:1 \text{ CDCl}_3:\text{CD}_3\text{OD}): 7.39 (1\text{H}, \text{d}, J = 9.0 \text{ Hz}), 7.11$ - 7.06 (2H, m), 6.90 (2H, tt, J= 9.0, 2.1 Hz), 4.46 (1H, d, J= 1.1 Hz, H-1), 4.17 (1H, dqd, J= 5.9, 4.0, 2.8, 1.7 Hz), 4.03 (1H, dd, J= 10.3, 3.8 Hz), 3.90 – 3.81 (2H, m, H-6), 3.74 – 3.66 (2H, m), 3.59 – 3.48 (3H, m), 3.42 (1H, dd, J= 9.4, 3.3 Hz), 3.20 (1H, ddd, J= 9.7, 5.8, 2.5 Hz), 2.53 (2H, t, J= 7.9 Hz), 2.16 (2H, t, J= 7.7 Hz), 1.47 – 1.65 (6H,m), 1.32 – 1.14 (40H, m), 0.84 (3H, t, J = 6.9 Hz,); $\delta_{C}(126$ MHz, 2:1 CDCl₃:CD₃OD): 174.66, 161.48 (d, ${}^{1}J_{CF} = 242.2$ Hz), 138.81 (d, ${}^{4}J_{CF}$ = 3.3 Hz), 129.96 (t, ${}^{3}J_{CF}$ = 8.0 Hz), 115.09 (d, ${}^{2}J_{CF}$ = 21.0 Hz), 100.39 (d,

 ${}^{1}J_{CH} = 157.4$ Hz, *C*-1), 76.87, 74.39, 74.14, 72.35, 71.11, 68.49, 67.52, 61.85, 50.50, 36.79, 35.40, 32.36, 32.23, 31.94, 30.10, 30.07, 30.03, 30.01, 29.98, 29.96, 29.88, 29.82, 29.81, 29.77, 29.76, 29.71, 29.68, 29.66, 29.49, 26.26, 26.19, 22.96, 14.22; $\delta_{F}(376 \text{ MHz}, 2:1 \text{ CDCl}_{3}:\text{CD}_{3}\text{OD}):$ -119.07 (tt, *J*= 9.1, 5.3 Hz); HRMS (ESI-pos): calcd for C₄₁H₇₂O₉NFNa [M + Na]⁺ *m/z* 764.5083 found *m/z* 764.5110; Anal. Calcd for C₄₁H₇₂NO₉·2H₂O: C, 66.37; H, 9.78; N, 1.89. Found C, 66.13; H, 9.49; N, 1.93.

1-[(2'S,3'S,4'R)-2'-[11''-(4-(4-Fluorophenoxy)phenyl)-undecamidyl]-3',4'-di-*O*-benzyl-1'-octadecanyl]-2,3-di-*O*-benzyl-4,6-*O*-benzylidene-β-D-mannopyranoside (27)

To a solution of azide 8 (α/β = 5:95) (148 mg, 0.154 mmol) in anhydrous THF (10 mL) at 0 °C under argon was added trimethylphosphine (1M in THF, 1.100 mL, 1.100 mmol). The solution was warmed to rt over 1 hr then stirred at rt for an additional 4 hrs. NaOH (2M, 4 mL) was added to the reaction mixture and the resulting solution stirred at rt overnight to hydrolyse the imino-phosphorane. The reaction was diluted with CH_2Cl_2 , washed with water and the volatiles were removed in vacuo to give amine intermediate 18 as a colourless oil. EDCI-HCl (94 mg, 0.490 mmol) and HOBt (81 mg, 0.585 mmol) were added to a stirred suspension of 11-(4-(4fluorophenoxy)phenyl)undecanoic acid 25 (82 mg, 0.220 mmol) in anhydrous CH₂Cl₂/DMF (10:4, 7 mL) at rt under argon. After 30 min a solution of 18 (143 mg, 0.154 mmol) in anhydrous CH₂Cl₂ (5 mL) was added followed by DIPEA (190 µL, 1.085 mmol) and the reaction stirred at rt overnight. The reaction was diluted with CH₂Cl₂, washed with water and the aqueous layer re-extracted with EtOAc. The combined organics were concentrated in vacuo to give the crude which was purified by column chromatography (PE, to 5:1 PE:EtOAc) to give the *title compound* **27** as a mixture of anomers ($\alpha/\beta = 5.95$) as a colourless oil. Data for β -**27**: $\delta_{\rm H}(500 \text{ MHz}, \text{CDCl}_3)$: inter alia 7.53 – 7.22 (25H, m), 7.14 – 7.09 (2H, m), 7.03 – 6.93 (4H, m), 6.91 – 6.85 (2H, m), 5.67 (1H, d, J= 8.3 Hz), 5.60 (1H, s), 4.89 (1H, d, J= 12.2 Hz), 4.80 (1H, d, J= 12.2 Hz), 4.75 (1H, d, J= 11.5 Hz), 4.69 (1H, d, J= 12.4 Hz), 4.61 (1H, d, J= 9.3 Hz), 4.59 (1H, d, J= 10.4 Hz), 4.56 (1H, d, J= 7.2 Hz), 4.53 (1H, d, J= 7.4 Hz), 4.42 – 4.35 (2H, m), 4.25 (1H, dd, J= 10.4, 4.9 Hz), 4.17 (1H, t, J= 9.5 Hz), 4.05 (1H, dd, J= 10.3, 7.9 Hz), 3.89 – 3.83 (2H, m), 3.80 – 3.74 (2H, m,), 3.55 (2H, m), 3.24 (1H, td, *J*= 9.7, 4.8 Hz), 2.56 (2H, t, J= 7.8 Hz), 1.94 (2H, qt, J= 14.6, 7.6 Hz), 1.72 – 1.55 (4H, m), 1.53 – 1.45 (2H, m), 1.33 - 1.21 (36H, m), 0.88 (3H, t, J = 6.8 Hz,); $\delta_{C}(126$ MHz, CDCl₃): 172.94, 158.73 (d, ${}^{1}J_{CF} = 241.2 \text{ Hz}$, 155.51, 153.52 (d, ${}^{4}J_{CF} = 2.4 \text{ Hz}$), 138.65, 138.62, 138.58, 138.43, 138.01 , 137.66, 129.70, 128.59, 128.57, 128.52, 128.45, 128.32, 128.04, 127.99, 127.82, 127.70 , 126.20, 120.20 (d, ${}^{3}J_{CF} = 8.1 \text{ Hz}$), 118.48, 116.29 (d, ${}^{2}J_{CF} = 23.3 \text{ Hz}$), 102.20 (d, ${}^{1}J_{CH} = 156.28$ Hz C-1), 101.59, 80.63, 79.71, 78.77, 77.94, 76.07, 74.83, 73.70, 72.58, 72.20, 68.70, 67.68, 49.94, 36.89, 35.35, 32.08, 31.78, 30.57, 29.96, 29.87, 29.85, 29.82, 29.74, 29.67, 29.65, 29.61, 29.53, 29.46, 26.05, 25.76, 22.84, 14.27; $\delta_{\rm F}(376 \text{ MHz}, \text{CDCl}_3)$: -121.12 (tt, *J*= 8.7, 4.7 Hz); HRMS (ESI-pos): calcd for C₈₂H₁₀₄O₁₀NFNa [M + Na]⁺ *m/z* 1304.7530 found *m/z* 1304.7536.

1-[(2'S,3'S,4'R)-2'-[11''-(p-(4-Fluorophenoxy)phenyl)-undecamidyl]-3',4'-di-*O*-acetyl-1'octadecanol]-2,3,4,6-tetra-*O*-acetyl-β-D-mannopyranoside (30)

To a solution of glycolipid 27 (134 mg, 0.104 mmol) in CH₂Cl₂/MeOH (1:1, 20 mL) was added 10% palladium on carbon (32 mg, 0.030 mmol). The stirred reaction mixture was degassed under vacuum and backfilled with hydrogen three times then left to stir overnight under a balloon of hydrogen. The hydrogen atmosphere and solvents were removed in vacuo to give the crude material which was precipitated by dissolving in hot ethanol and triturating out of solution with dropwise addition of water. Once a precipitate formed the mixture was heated to re-dissolve and the resulting solution was allowed to cool slowly to rt and then cooled in ice. The resulting precipitate was filtered through a Hirsch funnel and dried to a constant weight affording glycolipid **29** (82 mg, 0.098 mmol, 94%) as a white solid which contained traces of the α-anomer. Acetic anhydride (1 mL, 10.58 mmol) was added dropwise to a stirred solution of **29** in pyridine (1 mL, 12.41 mmol) at rt. The reaction was stirred at rt overnight, after which a standard aqueous workup was performed using EtOAc as the organic solvent. Additional washes of the organic extract were performed with 2M aqueous HCl and sat. aqueous NaHCO3 solutions. The combined organic extracts were concentrated *in vacuo* to give the crude material which was purified by column chromatography (PE, to 3:1 PE:EtOAc) to give the title *compound* **30** (79 mg, 0.073 mmol, 74%) as a colourless oil. $\delta_{\rm H}(500 \, \rm MHz, \rm CDCl_3)$: 7.14 – 7.08 (2H, m), 7.03 – 6.92 (4H, m), 6.91 – 6.83 (2H, m), 6.27 (1H, dd, J= 9.6, 3.5 Hz), 5.40 (1H, d, J= 3.4 Hz), 5.22 (1H, t, J= 9.9 Hz), 5.03 (2H, td, J= 9.9, 9.4, 2.9 Hz,), 4.82 (1H, dt, J= 10.2, 2.9 Hz), 4.54 (1H, s), 4.35 (1H, tt, J= 9.5, 2.9 Hz), 4.21 (1H, dd, J= 12.2, 5.3 Hz), 4.15 (1H, dd, J= 12.2, 2.7 Hz), 3.96 (1H, dd, J= 9.5, 2.8 Hz), 3.60 (1H, ddd, J= 10.1, 5.5, 2.7 Hz), 3.44 (1H, dd, J= 9.5, 2.7 Hz), 2.56 (2H, t, J= 7.8 Hz), 2.22 (2H, t, J= 7.7 Hz), 2.20 (3H, s), 2.08 (3H, s), 2.05 (3H, s), 2.04 (3H, s), 2.00 (6H, s), 1.60 (6H, dp, J= 20.9, 6.9 Hz), 1.38 - 1.17 (36H, m), 0.87 (3H, t, J= 6.4 Hz); $\delta_{C}(126 \text{ MHz}, \text{CDCl}_{3})$: 173.21, 171.34, 171.15, 170.64, 170.09, 169.72, 169.67, 158.69 (d, ${}^{1}J_{CF} = 241.1 \text{ Hz}$), 155.46, 153.53 (d, ${}^{4}J_{CF} = 2.4 \text{ Hz}$), 138.04, 129.70, 120.17 (d, ${}^{3}J_{CF} = 8.2 \text{ Hz}$), 118.46 , 116.26 (d, ${}^{2}J_{CF} = 23.2 \text{ Hz}$), 98.26 (d, ${}^{1}J_{CH} = 158.42$ Hz C-1), 73.48, 72.50, 71.27, 70.76, 68.63, 68.17, 66.19, 62.55, 47.41, 36.77, 35.33, 32.05, 31.77, 29.82, 29.78, 29.74, 29.69, 29.65, 29.62, 29.49, 29.47, 29.43, 27.73, 25.77, 25.74, 22.81, 21.15, 21.12, 20.83, 20.81, 20.79 (CH₃), 20.75, 20.73, 20.70, 14.24; δ_F(376 MHz, CDCl₃): -

121.17 (tt, J= 8.4, 4.7 Hz); HRMS (ESI-pos): calcd for C₅₉H₈₈O₁₆NFNa [M + Na]⁺ m/z 1108.5959 found m/z 1108.5979.

11-(4-(4-Fluorophenoxy)phenyl)-*N*-[(1*S*,2*S*,3*R*)-2,3-dihydroxy-1-[(β-D-mannopyranosyloxy)methyl]heptadecyl] undecanamide (29)

To a solution of peracetate 30 (69 mg, 0.064 mmol) in CH₂Cl₂/MeOH (2:4 mL) was added sodium methoxide solution (2.5M in MeOH, 40 µL, 0.100 mmol) and the reaction mixture was stirred at rt for 3 hrs. The reaction was diluted with CH₂Cl₂/MeOH (1:1, 20 mL) and the volatiles removed in vacuo. The resulting white solid was dissolved in hot EtOH, cooled to rt and placed in the freezer (-18°C) for an hr. The resulting precipitate was filtered and dried to a constant weight to afford the *title compound* **29** (45 mg, 0.054 mmol, 85%) as a white solid. δ_H(500 MHz, 2:1 CDCl₃:CD₃OD): 7.42 (1H, d, *J*= 8.7 Hz), 7.09 (2H, dt, *J*= 8.4, 2.7 Hz), 7.00 - 6.89 (4H, m), 6.86 - 6.82 (2H, m), 4.46 (1H, s), 4.17 (1H, dt, J= 6.4, 4.0 Hz), 4.04 (1H, dd, J= 10.3, 3.7 Hz), 3.89 – 3.81 (2H, m), 3.74 – 3.67 (2H, m), 3.62 – 3.50 (3H, m), 3.43 (1H, dd, J= 9.4, 3.3 Hz), 3.20 (1H, ddd, J= 9.6, 5.7, 2.5 Hz), 2.54 (2H, t, J= 7.8 Hz), 2.16 (2H, t, J= 7.6 Hz,), 1.68 - 1.47 (6H, m), 1.40 - 1.19 (42H, m), 0.84 (3H, t, J = 6.9 Hz); $\delta_{C}(126$ MHz, 2:1 CDCl₃:CD₃OD): 174.68, 158.97 (d, ${}^{1}J_{CF}$ =240.9 Hz), 155.69, 153.79 (d, ${}^{4}J_{CF}$ =2.4 Hz), 138.29, 129.91, 120.33 (d, ${}^{3}J_{CF}$ =8.2 Hz), 118.66 , 116.41 (d, ${}^{2}J_{CF}$ =23.4 Hz), 100.44 (d, ${}^{1}J_{CH}$ = 158.99 Hz C-1), 76.85, 74.37, 74.06, 72.39, 71.08, 68.65, 67.29, 61.58, 50.36, 36.77, 35.49, 32.34, 32.24, 31.97, 30.11, 30.08, 30.04, 30.02, 29.97, 29.92, 29.87, 29.82, 29.75, 29.71, 29.67, 29.60, 26.29, 26.22, 22.97, 14.22; δ_F(376 MHz, 2:1 CDCl₃:CD₃OD): -121.42 (tt, *J*= 8.3, 4.4 Hz); HRMS (ESI-pos): calcd for C₄₇H₇₆O₁₀NFNa $[M + Na]^+ m/z 856.5345$ found m/z 856.5348.

1-((2'*S*,3'*S*,4'*R*)-2'-[*N-tert*-butoxycarbonylamino]-3',4'-di-*O*-benzyl-1'-octadecanol)-2,3di-*O*-benzyl-4,6-*O*-benzylidene-β-D-mannopyranoside (31)

To a solution of azide **8** ($\alpha/\beta = 5:95$) (237 mg, 0.249 mmol) in anhydrous THF (10 mL) at 0 °C under argon was added trimethylphosphine (1M in THF, 1.100 mL, 1.100 mmol). It was warmed to rt over 1 hr and then stirred at rt for 4 hrs. NaOH (2M, 4 mL) was added to the reaction and the resulting solution stirred at rt. The reaction was diluted with CH₂Cl₂, washed with water and the volatiles were removed *in vacuo* to give a colourless oil. Di*-tert*-butyl dicarbonate (70 mg, 0.321 mmol) and DIPEA (260 μ L, 1.49 mmol) was added to a stirred solution of the intermediate in DMF (5mL) at rt. The reaction was heated to 50 °C overnight then allowed to cool to rt. The reaction was diluted with EtOAc and a standard aqueous workup was preformed using EtOAc as the organic solvent. The solvents were removed *in vacuo* to

afford a residue that was purified by column chromatography (PE, to 4:1 PE:EtOAc) to give the *title compound* **31** 199 mg, 0.194 mmol, 78%) as a colourless oil.

 $δ_{\rm H}(500 \text{ MHz}, {\rm CDCl}_3)$: 7.56 – 7.44 (4H, m), 7.42 – 7.26 (21H, m), 5.61 (1H, s), 4.96 (1H, d, *J*= 12.2 Hz), 4.86 (1H, d, *J*= 12.2 Hz), 4.80 (1H, d, *J*= 11.1 Hz), 4.71 (1H, d, *J*= 12.5 Hz), 4.66 – 4.58 (3H, m), 4.51 (1H, d, *J*= 11.6 Hz,), 4.39 (1H, s), 4.25 (1H, dd, *J*= 10.4, 4.8 Hz), 4.19 (1H, t, *J*= 9.6 Hz), 4.11 (1H, dd, *J*= 9.9, 6.5 Hz), 4.03 – 3.95 (1H, m), 3.92 (1H, d, *J*= 3.0 Hz), 3.87 (1H, t, *J*= 10.3 Hz), 3.77 (1H, dd, *J*= 7.0, 3.0 Hz), 3.66 (1H, dd, *J*= 10.1, 3.5 Hz), 3.56 (2H, td, *J*= 8.2, 7.0, 3.2 Hz), 3.26 (1H, td, *J*= 9.7, 4.8 Hz), 1.75 – 1.63 (2H, m, CH₂), 1.43 (9H, s), 1.22 – 1.23 (24H, d, *J*= 4.5 Hz), 0.90 (3H, t, *J*= 6.8 Hz); $δ_{\rm C}$ (126 MHz, CDCl₃): 155.44, 138.68, 138.66, 138.57, 138.47, 137.7, 128.99, 128.60, 128.53, 128.48, 128.46, 128.33, 128.31, 128.28, 128.26, 128.13, 128.06, 127.79, 127.74, 127.71, 127.69, 126.20, 102.16 (d, ¹*J*_{CH}= 155.94 Hz *C*-1), 101.56, 79.92, 79.80, 79.46, 78.81, 77.97, 75.83, 74.80, 74.06, 72.57, 71.99, 69.14, 68.70, 67.72, 51.16, 32.07, 29.88, 29.86, 29.84, 29.81, 29.51, 28.54, 26.05, 22.84, 14.27; HRMS (ESIpos): calcd for C₆₄H₈₅O₁₀NNa [M + Na]⁺ *m*/z 1050.6066 found *m*/z 1050.6088.

1-((2'S,3'S,4'R)-2'-Amino-1',3',4'-octadecanyl)-β-D-mannopyranoside.TFA salt (32)

To a solution of N-Boc glycoside 31 (199 mg, 0.194 mmol) in CH₂Cl₂/MeOH (1:1, 20 mL) was added 10% palladium on carbon (60 mg, 0.056 mmol). The stirred reaction mixture was degassed under vacuum and backfilled with hydrogen three times then left to stir overnight under a balloon of hydrogen. After dilution with hot EtOH the solution was filtered through Celite and washed with hot EtOH (50 mL). The solvents were removed in vacuo, the residue was dissolved in CH₂Cl₂ (5 mL). Trifluoroacetic acid (1 mL, 13.07 mmol) was added and the reaction was stirred at rt overnight before being diluted with CH₂Cl₂. The solvents removed in *vacuo* to give a residue which was purified by C18 reverse phase chromatography (Isolute C-18(EC)) with a gradient of H₂O and MeCN 80:20 to 0:100 eluting around 60:40). The fractions containing the target molecule were combined and lyophilized to give the *title compound* 32 (89 mg, 0.147 mmol, 77% over two steps) as a white solid. $\delta_{\rm H}(500 \text{ MHz}, 2:1, \text{CDCl}_3:\text{CD}_3\text{OD})$: 4.54 (1H, d, J= 0.9 Hz), 4.11 – 3.96 (2H, m), 3.93 (1H, d, J= 3.1 Hz), 3.90 (1H, dd, J= 11.9, 2.4 Hz), 3.71 (1H, dd, J= 11.9, 5.8 Hz), 3.62 (1H, dt, J= 8.7, 4.0 Hz), 3.58 – 3.52 (2H, m, H-4), 3.47 (1H, dd, J= 9.4, 3.2 Hz), 3.42 (1H, td, J= 8.4, 2.7 Hz), 3.23 (1H, ddd, J= 9.6, 5.8, 2.4 Hz), 1.76 (1H, ddd, J= 13.5, 7.1, 2.9 Hz), 1.43 -1.55 (1H, m), 1.42 - 1.15 (26H, m), 0.85 (3H, t, J = 6.9 Hz); $\delta_{\rm C}(126$ MHz, 2:1, CDCl₃:CD₃OD): 100.24 (d, ${}^{1}J_{\rm CH} = 158.29$ Hz C-1), 77.38, 74.15, 72.95, 72.30, 71.42, 67.56, 65.77, 61.90, 54.42, 34.79, 32.45, 30.23, 30.20, 30.19, 30.16, 29.86, 25.74, 23.16, 14.29; $\delta_F(376 \text{ MHz}, 2:1, \text{CDCl}_3:\text{CD}_3\text{OD}):$ -76.15; HRMS (ESI-pos): calcd for C₂₄H₅₀O₈N [M + H]⁺ *m/z* 480.3531 found *m/z* 480.3508.

1-[(2'*S*,3'*S*,4'*R*)-2'-*N*-[(11*Z*,14*Z*)-1''-oxo-11'',14''-eicosadien-1''-yl]-3',4'-di-*O*-acetyl-1'octadecanyl]-2,3,4,6-tetra-*O*-acetyl-β-D-mannopyranoside (34)

To a mixture of cis-11,14-elicosadienoic acid (42 mg, 0.133 mmol) in anhydrous CH₂Cl₂ (5mL) under an argon atmosphere and with the exclusion of light, was added TEA (300 μ L, 2.137 mmol) then isopropyl chloroformate solution (130 µL, 0.130 mmol) and the resulting solution was stirred at rt for 50 min to give the crude mixed carbonic anhydride. This was added to a solution of **33** (62 mg, 0.104 mmol) in anhydrous DMF (5 mL) at 0 °C under argon and with the exclusion of light. After 5 min the ice bath was removed and the reaction was warmed to rt. When TLC indicated loss of starting material and formation of the amide intermediate (approx. 3 hrs), acetic anhydride (600 µL, 6.35 mmol) and DMAP (1 crystal) were added to the reaction mixture and the reaction was stirred at rt overnight. The reaction was diluted with CH₂Cl₂, washed with water and brine and concentrated *in vacuo* to give the residue that was purified by column chromatography (PE to 2:1 PE/EtOAc) to give the title compound 34 (91 mg, 0.089 mmol, 86%) as a colourless oil. $\delta_{\rm H}(500 \text{ MHz}, \text{ acetone-}d_6)$: 7.18 (1H, d, J = 9.4 Hz,NH), 5.45 – 5.31 (5H, m), 5.19 (1H, t, J= 9.9 Hz), 5.12 (2H, dd, J= 10.1, 3.2 Hz), 4.96 (1H, dt, J= 10.6, 2.9 Hz), 4.92 (1H,), 4.40 (1H, ddd, J= 14.1, 6.9, 4.3 Hz), 4.27 (1H, dd, J= 12.1, 5.5 Hz), 4.15 (1H, dd, J= 12.2, 2.5 Hz), 4.00 (1H, dd, J= 10.0, 4.7 Hz), 3.88 (1H, ddd, J= 9.7, 5.5, 2.6 Hz), 3.59 (1H, dd, J= 10.0, 2.9 Hz), 2.83 (2H, t, J= 7.0 Hz), 2.25 – 2.16 (2H, m), 2.14 (3H, s), 2.08 (3H, s), 2.06 (3H, s), 2.04 (3H, s), 1.98 (3H, s), 1.95 (3H, s), 1.83 – 1.74 (1H, m), 1.70 - 1.57 (3H, m), 1.26 - 1.44 (46H,m), 0.91 (6H, app q, J = 6.5 Hz); $\delta_{C}(126$ MHz, Acetone*d*₆): 172.95, 170.98, 170.75, 170.72, 170.20, 170.17, 170.15, 130.70, 130.68, 128.78, 128.77 (C-12''), 98.73 (d, ${}^{1}J_{CH} = 160.16$ Hz C-1), 73.56, 72.91, 72.50, 71.82, 69.54, 69.11, 66.95, 63.16, 48.18, 36.72, 32.66, 32.25, 30.45, 30.40, 30.37, 30.32, 30.28, 30.25, 30.10, 30.07, 30.06, 29.94, 28.47, 27.87, 27.81, 26.46, 26.31, 26.23, 23.35, 23.23, 20.99, 20.83, 20.71, 20.68, 20.54, 14.38, 14.36; HRMS (ESI-pos): calcd for C₅₆H₉₅O₁₅NNa $[M + Na]^+ m/z$ 1044.6594 found m/z1044.6604.

N-[(1*S*,2*S*,3*R*)-2,3-Dihydroxy-1-[(β-D-mannopyranosyloxy)methyl]heptadecyl]-11*Z*, 14*Z*-eicosadienamide (33)

To a solution of glycolipid **34** (32 mg, 0.032 mmol) in CH₂Cl₂/MeOH (2:4, 10 mL) under argon with the exclusion of light was added sodium methoxide solution (2.5M in MeOH, 30.0 μ L,

0.075 mmol) and the reaction mixture was stirred at rt for 3 hours. The reaction was diluted with CH₂Cl₂/MeOH (1:1, 20 mL) and the volatiles removed in vacuo. The residue was dissolved in minimal ethanol and transferred to a 14 mL centrifuge tube and 10 mL water was added causing a milky white suspension to form. The tube was spun at 5200 rpm for 25 min before the aqueous layer was decanted leaving behind a white solid. The solid was resuspended in 10 mL water and spun again to further wash the solid, again decanting the aqueous layer. The combined aqueous layers were evaporated to dryness and the procedure repeated to obtain further solid. The solids were dissolved in ethanol, transferred to a round bottom flask, concentrated in vacuo, and dried to a constant weight to afford the *title compound* 33 (22 mg, 0.028 mmol, 88%) as a white solid. $\delta_{H}(500 \text{ MHz}, 2:1 \text{ CDCl}_{3}:\text{CD}_{3}\text{OD}): 5.39 - 5.23 (4H, m),$ 4.46 (1H, s), 4.17 (1H, dt, J= 7.0, 3.9 Hz), 4.06 (1H, dd, J= 10.2, 3.6 Hz), 3.88 (1H, d, J= 3.1 Hz), 3.83 (1H, dd, J= 12.0, 2.5 Hz), 3.71 (2H, ddd, J= 17.9, 11.1, 4.6 Hz), 3.62 – 3.49 (3H, m), 3.43 (1H, dd, *J*= 9.3, 3.2 Hz), 3.19 (1H, ddd, *J*= 9.6, 5.2, 2.5 Hz), 2.73 (2H, t, *J*= 6.8 Hz), 2.16 (2H, t, J= 7.7 Hz), 2.01 (4H, q, J= 7.0 Hz), 1.63 – 1.46 (4H, m), 1.40 – 1.17 (48H, m), 0.85 (6H, q, J= 6.7 Hz); $\delta_{C}(126 \text{ MHz}, 2:1 \text{ CDCl}_{3}:\text{CD}_{3}\text{OD})$: 174.68, 130.44, 130.37, 128.29, 128.25, 100.41 (d, ${}^{1}J_{CH} = 156.97$ Hz, C-1), 76.90, 74.41, 74.16, 72.36, 71.13, 68.51, 67.53, 61.87, 50.52, 36.81, 32.38, 32.25, 31.85, 30.12, 30.09, 30.05, 30.03, 30.02, 29.98, 29.90, 29.87, 29.77, 29.73, 29.68, 29.66, 29.65, 27.54, 27.50, 26.28, 26.22, 25.92, 22.98, 22.87, 14.23, 14.20. HRMS (ESI-pos): calcd for C₄₄H₈₃O₉NNa $[M + Na]^+ m/z$ 792.5960 found m/z 792.5940.

Figures for Supporting Information

Figure SI-1 Stacked ¹H NMR partial spectra of α-ManCer (20)(top) and β-ManCer (2) (bottom)







Effects of α -ManCer (**20**) and α -ManPhyt (**23**) compared to vehicle (PBS/TWEEN20) and β -ManCer at 5000 and 50 pmol. (N=8 mice/group) *p<0.05 compared with vehicle control (Mann-Whitney).

NMR Spectra and HPLC Chromatograms

Compound 8 (method 2). ¹H NMR spectrum (500 MHz, CDCl₃).




























Compound **17**. ¹H NMR spectrum (500 MHz, CDCl₃).





Compound **19**. ¹H NMR spectrum (500 MHz, CDCl₃).





Compound 2. ¹H NMR spectrum (500 MHz, 2:1 CDCl₃:CD₃OD).





Compound 2. ¹³C NMR spectrum (125 MHz, 2:1 CDCl₃:CD₃OD).





Figure SI-### Stacked ¹H NMR partial spectra of α -ManCer **20**(top) and β -ManCer **2** (bottom)





Synthetic purity assessment: Analytical HPLC [Phenomenex Kinetex 100Å C18 (2.6 μ m, 3.0 x 50 mm), line A = H₂O, line B = CH₃OH, both modified with 0.5% TFA, flow rate = 0.50 mL min⁻¹, gradient = 60% -100% line B (4 mins), 100% line B(8 mins), 100% - 60% line B (1 min), 60% line B (2 mins), t_R = 7.504 min (95.1%).





Compound 22. ¹³C NMR spectrum (125 MHz, CDCl₃).

Compound 23. ¹H NMR spectrum (500 MHz, 2:1 CDCl₃:CD₃OD).





Compound 23. ¹³C NMR spectrum (125 MHz, 2:1 CDCl₃:CD₃OD).



Synthetic purity assessment: Analytical HPLC [Phenomenex Kinetex 100Å C18 (2.6 μ m, 3.0 x 50 mm), line A = H₂O, line B = CH₃OH, both modified with 0.5% TFA, flow rate = 0.50 mL min⁻¹, gradient = 60% -100% line B (4 mins), 100% line B(8 mins), 100% - 60% line B (1 min), 60% line B (2 mins), t_R = 3.57 min (91.3%).

Compound **20**. ¹H NMR spectrum (500 MHz, 2:1 CDCl₃:CD₃OD).





Compound 20. ¹³C NMR spectrum (125 MHz, 2:1 CDCl₃:CD₃OD).





Synthetic purity assessment: Analytical HPLC [Phenomenex Kinetex 100Å C18 (2.6 μ m, 3.0 x 50 mm), line A = H₂O, line B = CH₃OH, both modified with 0.5% TFA, flow rate = 0.50 mL min⁻¹, gradient = 60% -100% line B (4 mins), 100% line B(8 mins), 100% - 60% line B (1 min), 60% line B (2 mins), t_R = 7.379 min (96.6%).

Compound **26**. ¹H NMR spectrum (500 MHz, CDCl₃).







Compound 27. ¹H NMR spectrum (500 MHz, CDCl₃). β : α = 95:5











Compound **28**. ¹⁹F NMR spectrum (376 MHz, 2:1 CDCl₃:CD₃OD)



f1 (ppm)



Synthetic purity assessment: Analytical HPLC [Phenomenex Kinetex 100Å C18 (2.6 μ m, 3.0 x 50 mm), line A = H₂O, line B = CH₃OH, both modified with 0.5% TFA, flow rate = 0.50 mL min⁻¹, gradient = 60% -100% line B (4 mins), 100% line B(8 mins), 100% - 60% line B (1 min), 60% line B (2 mins), t_R = 5.211 min (96.2%)

Compound **30**. ¹H NMR spectrum (500 MHz, CDCl₃).







Compound **30**. ¹⁹F NMR spectrum (376 MHz, CDCl₃).



Compound **29**. ¹H NMR spectrum (500 MHz, 2:1 CDCl₃:CD₃OD).



Compound **29**. ¹⁹F NMR spectrum (376 MHz, 2:1 CDCl₃:CD₃OD)

-60









Synthetic purity assessment: Analytical HPLC [Phenomenex Kinetex 100Å C18 (2.6 μ m, 3.0 x 50 mm), line A = H₂O, line B = CH₃OH, both modified with 0.5% TFA, flow rate = 0.50 mL min⁻¹, gradient = 60% -100% line B (4 mins), 100% line B(8 mins), 100% - 60% line B (1 min), 60% line B (2 mins), t_R = 5.40 min (94.8%).




S73



Compound **32**. ¹H NMR spectrum (500 MHz, 2:1 CDCl₃:CD₃OD).



Compound **32**. ¹⁹F NMR spectrum (376 MHz, 2:1 CDCl₃:CD₃OD)





S77

HPLC chromatogram of **32**



Synthetic purity assessment: Analytical HPLC [Phenomenex Kinetex 100Å C18 (2.6 μ m, 3.0 x 50 mm), line A = H₂O, line B = CH₃OH, both modified with 0.5% TFA, flow rate = 0.50 mL min⁻¹, gradient = 60% -100% line B (4 mins), 100% line B(8 mins), 100% - 60% line B (1 min), 60% line B (2 mins), t_R = 3.572 min (87.2492%).





Compound **33**. ¹³C NMR spectrum (125 MHz, 2:1 CDCl₃:CD₃OD).





HPLC chromatogram of 33



S

Synthetic purity assessment: Analytical HPLC [Phenomenex Kinetex 100Å C18 (2.6 μ m, 3.0 x 50 mm), line A = H₂O, line B = CH₃OH, both modified with 0.5% TFA, flow rate = 0.50 mL min⁻¹, gradient = 60% -100% line B (4 mins), 100% line B(8 mins), 100% - 60% line B (1 min), 60% line B (2 mins), t_R = 5.758 min (94.7%)





Compound **34**. ¹³C NMR spectrum (125 MHz, (CD₃)₂CO).

References

- 1. *Application: US; US Pat.,* 2012-13582612, 8835613, 2014.
- 2. K. Clark, J. Yau, A. Bloom, L. Pasquet, A. Berzofsky Jay, J. Wang, M. Zajonc Dirk, J. Venzon David, M. Suzuki, J. Compton Benjamin, F. Painter Gavin, L. Cardell Susanna, A. Porcelli Steven, M. Zajonc Dirk and M. Terabe, *Front. Immunol.*, 2019, **10**, 2355.
- 3. N. Okamoto, O. Kanie, Y.-Y. Huang, R. Fujii, H. Watanabe and M. Shimamura, *Chem. Biol.*, 2005, **12**, 677-683.
- 4. Z. Liu and R. Bittman, *Org. Lett.*, 2012, **14**, 620-623.
- 5. L. Panza, F. Compostella and D. Imperio, *Carbohydr. Res.*, 2019, **472**, 50-57.